期刊文献+

Endoscopic ablation of Barrett's esophagus using high power setting argon plasma coagulation: A prospective study 被引量:14

Endoscopic ablation of Barrett's esophagus using high power setting argon plasma coagulation: A prospective study
暂未订购
导出
摘要 AIM: This prospective study evaluated the effectiveness of 90 W argon plasma coagulation (APC) for the ablation of Barrett's esophagus (BE) that is considered to be the main risk factor for the development of esophageal adenocarcinoma.METHODS: The results from 25 patients, observed at the First Department of General Surgery, University of Verona, Italy, from October 2000 to October 2003, who underwent APC for histologically proven BE were prospectively analyzed.RESULTS: The ablation treatment was completed in all the patients but one (96%). The mean number of APC sessions needed to complete ablation was 1.6 (total number: 40). The eradication was obtained in the majority of cases by one session only (60%), two sessions were required in 24% of the cases and three or more in 16%.About 43% of the sessions were complicated. Retrosternal pain (22.5%) and fever (17.5%) were the most frequent symptoms. Only one major complication occurred, it was an hemorrhage due to ulcer formation on the treated esophagus that required urgent endoscopic sclerosis and admission. The follow-up was accomplished in all the patients with a mean period of 26.3 mo and 20 patients (84%) with a follow-up period longer than 24 mo. Only one patient showed a relapse of metaplastic mucosa 12 mo after the completion of ablation. The patient was hence re-treated and now is free from recurrence 33 mo later.CONCLUSION: High power setting (90 W) APC showed to be safe and effective. The effects persist at a mean follow-up period of two years with a comparable cost in term of complications with respect to standard power settings. Further studies with greater number of patients are required to confirm these results and to assess if ablation reduces the incidence of malignant progression. AIM: This prospective study evaluated the effectiveness of 90 W argon plasma coagulation (APC) for the ablation of Barrett's esophagus (BE) that is considered to be the main risk factor for the development of esophageal adenocarcinoma. METHODS: The results from 25 patients, observed at the First Department of General Surgery, University of Verona, Italy, from October 2000 to October 2003, who underwent APC for histologically proven BE were prospectively analyzed, RESULTS: The ablation treatment was completed in all the patients but one (96%). The mean number of APC sessions needed to complete ablation was 1.6 (total number: 40). The eradication was obtained in the majority of cases by one session only (60%), two sessions were required in 24% of the cases and three or more in 16%. About 43% of the sessions were complicated. Retrosternal pain (22.5%) and fever (17.5%) were the most frequent symptoms. Only one major complication occurred, it was an hemorrhage due to ulcer formation on the treated esophagus that required urgent endoscopic sclerosis and admission. The follow-up was accomplished in all the patients with a mean period of 26.3 mo and 20 patients (84%) with a follow-up period longer than 24 mo. Only one patient showed a relapse of metaplastic mucosa 12 mo after the completion of ablation. The patient was hence re-treated and now is free from recurrence 33 mo later. CONCLUSION: High power setting (90 W) APC showed to be safe and effective. The effects persist at a mean follow-up period of two years with a comparable cost in term of complications with respect to standard power settings. Further studies with greater number of patients are required to confirm these results and to assess if ablation reduces the incidence of malignant progression.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第12期1872-1875,共4页 世界胃肠病学杂志(英文版)
关键词 Barrett's esophagus Argon plasma coagulation Endoscopic treatment 内窥镜切除手术 巴雷特氏食道 氩离子凝结 食道癌 病理机制
  • 相关文献

参考文献1

二级参考文献17

  • 1Spechler SJ. Barrett's esophagus and esophageal adenocarcinorna:pathogenesis, diagnosis, and therapy. Med Clin North Am 2002;86:1423-1445.
  • 2Reynolds JC, Rahimi P, Hirschl D. Barrett's esophagus: clinical characteristics. Gastroenterol Clin North Am 2002; 31:441-460.
  • 3Cossentino MJ, Wong RK. Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis 2003; 14:128-135.
  • 4Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States:racial and gender differences between histological type. Scand J Gastroenterol 2002; 37:1359-1365.
  • 5Vega KJ, Jamal MM. Changing pattern of esophageal cancer incidence in New Mexico. Am J Gastroenterol 2000; 95:2352-2356.
  • 6Li K, Yu P. Food groups and risk of esophageal cancer in Chaoshan region of China: a high-risk area of esophageal cancer.Cancer Invest 2003; 21:237-240.
  • 7Klimstra DS. Pathologic prognostic factors in esophageal carcinoma. Semin Oncol 1994; 21:425-430.
  • 8Stathopoulos GP, Tsiaras N. Epidemiology and pathologenesis of esophageal cancer management and its controversial results(review). Oncol Rep 2003; 10:449-454.
  • 9Lu JB, Sun XB, Dai DX, Zhu SK, Chang QL, Liu SZ, Duan WJ.Epidemiology of gastroenterologic cancer in Henan Province,China. World J Gastroenterol 2003; 9:2400-2403.
  • 10Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol 1994; 21:403-410.

共引文献21

同被引文献52

引证文献14

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部